Overview

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, open-label, multi-center study to assess the efficacy, safety, tolerability, pharmacokinetics, including recommended phase 2 dose (RP2D) of HM43239 monotherapy in subjects with relapsed or treatment-refractory acute myeloid leukemia (AML).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Hanmi Pharmaceutical Company Limited